Dear Sir, Several pieces of evidence suggest that plasma fibronectin (FN) has an important role in removal from circulation and processing of immune complexes (IC). Specific FN membrane receptors able to enhance IC inter-nalization via Fc receptors have been shown on mononuclear phagocyte system cells [1]. FN binding accelerates IC clearance from circulation and inhibits IC deposition in the mesangial area [2]. It was recently shown that IgA antibodies from patients with primary IgA nephropathy (IgAN) binds to collagen via a collagen-binding site of FN [3]. We observed that circulating IgA-FN aggregate (IgAFN-Ag) levels were related to the rate of removal from circulation of a recently proposed test probe for IgA-containing IC kinetic studies, i.e. an aggregated mixture of IgAl and IgG [4]. Moreover 93.3% of 30 patients with IgAN were found to have IgAFN-Ag compared to 11.7% of 103 patients with other types of glomerulonephritis (GN) [5]. It was concluded that IgAFN-Ag is a useful serological marker for IgAN and may be involved in the pathogenesis of this disease [5]. We examined 100 sera from 58 adult patients with IgAN [idiopathic in 51, associated with Henoch-Schönlein purpura (HSP) in 7]. Control groups included 14 lupus GN patients, 9 patients with membranous GN and 9 patients with alcoholic cirrhosis without urinary abnormalities. The Bio-Carb Diagnostics (Lund, Sweden) enzyme-linked immuno-sorbent assay was used. Results were calculated by subtracting absorbance at time 0 from absorbance at time 60 min for each well. Controls included three dilutions of a positive standard serum and a normal serum sample provided by the manufacturer, 4 sera (2 positive and 2 negative in previous assays) collected form the personal case report and a pool of 33 sera from 15 healthy subjects. Assay-to-assay variations were corrected by multipling the OD value of the test specimen by the quotient obtained by dividing the mean OD in 20 healthy controls by the pool value of the daily protocol. Values exceeding the
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In vitro experiments showed that interaction between IgA and FN is a normal process enhanced in IgAN [6] . This enhancement was reported to relate with plasma levels of , which is in agreement with our observation of a significant relationship between IgAFN-Ag and total IgA levels. Presently, however, the pathogenetic relevance of circulating IgAFN-Ag remains doubtful.
